Cefdinir Dispersible Tablets

1. Antibacterial effect It has a wide range of antibacterial spectrum against Gram-positive and Gram-negative bacteria, especially against Staphylococcus and Streptococcus among Gram-positive bacteria. It has stronger antibacterial activity than previous oral cephalosporins, and its mode of action is bactericidal. It is stable to beta-lactamase produced by various bacteria, and also has excellent antibacterial activity against beta-lactamase producing bacteria. 2. Mechanism of action The mechanism of action is to prevent the synthesis of bacterial cell walls, and has a strong affinity for penicillin binding proteins (PBP) 1 (1a.lbs), 2, and 3, but the active sites for different bacteria are different.

Cefdinir

This product is slightly yellow to yellow tablets.

The following infections caused by strains of Staphylococcus, Streptococcus, Pneumococcus, Peptostreptococcus, Propionibacterium, Neisseria gonorrhoeae, Moraxella catarrhalis, Escherichia coli, Klebsiella, Proteus mirabilis, Providencia, Haemophilus influenzae, etc. that are sensitive to cefdinir: 1. Pharyngitis, tonsillitis, acute bronchitis, pneumonia; 2. Otitis media, sinusitis; 3. Pyelonephritis, cystitis, gonococcal urethritis; 4. Adnexitis, intrauterine infection, vestibular gland inflammation; 5. Mastitis, perianal abscess, secondary infection of trauma or surgical wound; 6. Folliculitis, furuncle, furuncle, carbuncle, infectious impetigo, erysipelas, cellulitis, lymphangitis, paronychia, subcutaneous abscess, atheroma infection, chronic pyoderma; 7. Blepharitis, sty, tarsal gland inflammation

Disperse with water and take orally or swallow directly. The usual dose for adults is 0.1g (potency) once, 3 times a day. The usual dose for children is 9-18mg (potency)/kg per day, taken orally 3 times. The dose can be increased or decreased according to age and symptoms.

Among the 13,715 patients treated with this product, 354 cases (2.58%) reported adverse reactions (including abnormal laboratory data). The main adverse reactions were gastrointestinal symptoms (110 cases, 0.80%), such as diarrhea or abdominal pain; skin symptoms (31 cases, 0.23%), such as rash or itching. The main laboratory data abnormalities included elevated alanine aminotransferase (126 cases, 0.92%) and aspartate aminotransferase (89 cases, 0.65%); eosinophilia (41 cases, 0.30%). Other adverse reactions 1. Dermatology: Stevens-Johnson syndrome (0.1%) or toxic epidermal necrolysis (0.1%) may occur. Patients should be closely observed. If fever, headache, joint pain, erythema/blisters on the skin or mucous membranes, or tightness/burning/pain in the skin occur, the drug should be discontinued immediately and appropriate treatment should be given. 2. Allergic reactions: Allergic reactions may occur, such as dyspnea, erythema, angioedema, and urticaria, with an incidence of 0.1%. Patients should be closely observed. If abnormal conditions occur, the drug should be discontinued immediately and appropriate treatment should be given. 3. Shock: Shock may occur, with an incidence of 0.1%. Patients should be closely observed. If symptoms such as discomfort, oral discomfort, wheezing, dizziness, urge to defecate, tinnitus, or sweating occur, the drug should be discontinued immediately and appropriate treatment should be given. 4. Hematology: Pancytopenia (0.1%), agranulocytosis (0.1%, initial symptoms are fever, sore throat, headache, discomfort), thrombocytopenia (0.1%, initial symptoms are ecchymosis, purpura) or hemolytic anemia (0.1%, initial symptoms are fever, hemoglobinuria, anemia symptoms) may occur. Patients should be closely observed. If abnormal conditions occur, the drug should be discontinued immediately and appropriate treatment should be given. 5. Colitis: Severe colitis (0.1%) may occur, such as pseudomembranous colitis confirmed by bloody stools. Patients should be closely observed. If symptoms such as abdominal pain or frequent diarrhea occur, the drug should be discontinued immediately and appropriate treatment should be given. 6. Interstitial pneumonia or PIE syndrome: Interstitial pneumonia or PIE syndrome confirmed by fever, cough, dyspnea, abnormal chest X-ray examination or eosinophilia may occur (0.1%). If such symptoms occur, the drug should be discontinued immediately and appropriate treatment should be given, such as the use of adrenocortical hormones. 7. Kidney disease: Severe kidney disease (0.1%), such as acute renal failure, may occur. Patients should be closely observed. If abnormal conditions occur, the drug should be discontinued immediately and appropriate treatment should be given. 8. Fulminant hepatitis, abnormal liver function or jaundice: Severe hepatitis (0.1%), such as fulminant hepatitis with significant elevation of alanine aminotransferase, aspartate aminotransferase or alkaline phosphatase, abnormal liver function (0.1%) or jaundice (0.1%) may occur. Patients should be closely observed. If abnormal conditions occur, the drug should be discontinued immediately and appropriate treatment should be given.

Patients with a history of shock should not use this product. Patients with a history of allergy to penicillin or cephalosporin should use it with caution.

Precautions for children: The safety of medication for premature infants and newborns with low body weight has not been established. Precautions for pregnancy and lactation: The safety of medication during pregnancy has not been established. For pregnant women or women suspected of being pregnant, the pros and cons of medication should be weighed, and it can only be used when the benefits outweigh the risks. The pros and cons of medication for lactating women should be weighed, and it can only be used when the benefits outweigh the risks. Precautions for the elderly: Elderly patients should pay special attention to the following aspects when using this product, and adjust the dosage and dosing interval based on clinical observations of the patients: 1. Elderly patients may be prone to adverse reactions due to decreased physical function. 2. Elderly patients may have a tendency to bleed due to vitamin K deficiency.

It has been reported that some patients may prolong bleeding time and prothrombin time when using this product, so patients receiving anticoagulant therapy should use this product with caution. Like other broad-spectrum antibiotics, the combination of this product with oral contraceptives can reduce the efficacy of the latter, which should be stated in advance. ? It is not recommended to use this product in combination with probenecid, which can reduce the secretion of amoxicillin by the renal tubules. Combined use can lead to an increase in the blood concentration of amoxicillin and a prolongation of its half-life, but does not affect the blood concentration of clavulanic acid. ? Although there is no data on the combination of this product with allopurinol, the combination of amoxicillin and allopurinol can increase the possibility of allergic skin reactions. Be cautious when using this product in combination with the following drugs.

Keep in a dark place (avoid light and not exceed 20℃) and sealed.

0.1g

Tentative 24 months

Sinopharm ZHIJUN(Shenzhen)PHARMACEUTICAL Co., Ltd.

• Founded in:

  1985-12-11

• Address:

  No. 16, Lanqing 1st Road, Guanlan High-tech Park, Longhua New District, Shenzhen

• Tax NO.:

  91440300192190290M

• Registered Funds:

  200 million yuan

• Website:

  Log in to view

• Email:

  Log in to view